RPG Life Sciences Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Latest quarter profit grew 162.1% YoY, showing strong momentum
- Company has been maintaining a healthy dividend payout of 34.5%
- Company comfortably covers its interest (88.1x coverage)
CONS
- Receivables are growing faster than sales - a possible quality concern
- Stock is trading at 5.1x its book value
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| RPGLIFE | 2694.75 | 38.70 | 4456.85 | 0.89 | 307.60 | 162.12 | 1956.90 | 1267.60 | 26.99 | 22.12 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| 173 | 143 | 169 | 180 | 177 | 196 | |
| 124 | 118 | 139 | 140 | 144 | 159 | |
| Operating Profit | 49 | 25 | 30 | 40 | 33 | 37 |
| OPM % | 28.46% | 17.81% | 17.88% | 22.09% | 18.56% | 18.78% |
| 3 | 115 | 5 | -5 | 14 | 5 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 5 | 5 | 5 | 5 | 6 | 6 |
| Profit before Tax | 47 | 135 | 35 | 29 | 40 | 41 |
| Tax % | 25.51% | 13.01% | 25.80% | 24.00% | 25.62% | 25.81% |
| Net Profit | 0 | 0 | 26 | 22 | 30 | 31 |
| 21.12 | 70.96 | 15.90 | 13.38 | 18.08 | 18.60 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| 653 | 708 | 722 | |
| 494 | 560 | 582 | |
| Operating Profit | 159 | 148 | 140 |
| OPM % | 24.33% | 20.91% | 19.34% |
| 97 | 29 | 18 | |
| Interest | 2 | 2 | 1 |
| Depreciation | 21 | 21 | 22 |
| Profit before Tax | 233 | 154 | 146 |
| Tax % | 21.32% | 25.31% | 25.39% |
| Net Profit | 183 | 115 | 109 |
| EPS | 110.80 | 69.64 | — |
| Dividend Payout % | 21.66% | 34.46% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- 18%
- 5 Years:
- 35%
- 3 Years:
- 32%
- 1 Year:
- 13%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- Last Year:
- 20%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 13 | 13 |
| 517 | 592 | |
| 3 | 17 | |
| Trade Payables | 79 | 97 |
| 44 | 74 | |
| Total Liabilities | 657 | 793 |
| 172 | 197 | |
| Capital Work in Progress | 4 | 20 |
| 127 | 85 | |
| 93 | 124 | |
| 87 | 117 | |
| Cash & Bank | 140 | 192 |
| 35 | 60 | |
| Total Assets | 657 | 793 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 78 | 57 | |
| Cash from Investing | -42 | 86 |
| Cash from Financing | -27 | -21 |
| 9 | 122 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-09 - Update on Investment and Shareholders Agreement entered on July 29, 2026, subsidiary of the Company allotted securities to the Investors.
2026-09-04 - RPG Life Sciences Limited has informed the Exchange about Link of Recording
2026-09-03 - RPG Life Sciences Limited has informed the Exchange about Investors meet dail in details
2026-09-02 - RPG Life Sciences Limited has informed the Exchange about Investor Presentation
2026-09-02 - RPG Life Sciences Limited has informed the Exchange about Schedule of meet
2026-09-02 - Press Release
2026-09-02 - Intimation of execution of Business Transfer Agreement by its wholly owned subsidiary, RPG Active Pharma Limited with Raghava Life Sciences Private Limited
2026-09-02 - Outcome of Board Meeting
2026-09-01 - Cancellation of Investor meet
News
Recent coverage and analyst commentary for RPGLIFE
Loading news…
AI Stock Analyst
RPG Life Sciences Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account